Skip to main content
Erschienen in: Hepatology International 5/2016

31.05.2016 | Editorial

Targeting the renin–angiotensin system in liver fibrosis

verfasst von: Pau Sancho-Bru, Pere Ginès

Erschienen in: Hepatology International | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Excerpt

Liver fibrosis is the progressive accumulation of extracellular matrix (ECM) in the liver as a result of a persistent liver injury. If fibrogenesis persists, the accumulation of ECM disrupts the liver architecture leading to cirrhosis, the most advanced stage of liver disease, and portal hypertension, with the subsequent development of complications of cirrhosis. Two important components determine the increased portal pressure, first a structural component, which is mainly the accumulation of ECM that disturbs normal blood flow in the liver, and second, a dynamic component, which is the result of a high intrahepatic contractility and swelling, resulting from the activation of hepatic stellate and liver myofibroblasts and an increased liver inflammation [1]. …
Literatur
1.
Zurück zum Zitat Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011;6:425–456 Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011;6:425–456
2.
Zurück zum Zitat Cárdenas A, Ginès P. Portal hypertension. Curr Opin Gastroenterol 2009;25:195–201 Cárdenas A, Ginès P. Portal hypertension. Curr Opin Gastroenterol 2009;25:195–201
3.
Zurück zum Zitat Seo YS, Shah VH. Pathophysiology of portal hypertension and its clinical links. J Clin Exp Hepatol 2011;1:87–93 Seo YS, Shah VH. Pathophysiology of portal hypertension and its clinical links. J Clin Exp Hepatol 2011;1:87–93
4.
Zurück zum Zitat Bataller R, Sancho-Bru P, Ginès P, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003;125:117–125 Bataller R, Sancho-Bru P, Ginès P, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003;125:117–125
5.
Zurück zum Zitat Bataller R, Sancho-Bru P, Ginès P, Brenner DA. Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid Redox Signal 7:1346–1355 Bataller R, Sancho-Bru P, Ginès P, Brenner DA. Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid Redox Signal 7:1346–1355
6.
Zurück zum Zitat Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 2002;123:1667–1676 Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 2002;123:1667–1676
7.
Zurück zum Zitat Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW. Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. Clin Sci (Lond) 2012;123:225–239 Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW. Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. Clin Sci (Lond) 2012;123:225–239
8.
Zurück zum Zitat Moreira de Macêdo S, Guimarães TA, Feltenberger JD, Sousa Santos SH. The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. Peptides 2014;62:189–196 Moreira de Macêdo S, Guimarães TA, Feltenberger JD, Sousa Santos SH. The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. Peptides 2014;62:189–196
9.
Zurück zum Zitat Heller J, Shiozawa T, Trebicka J, Hennenberg M, Schepke M, Neef M, Sauerbruch T. Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats. Eur J Clin Invest 2003;33:1006–1012 Heller J, Shiozawa T, Trebicka J, Hennenberg M, Schepke M, Neef M, Sauerbruch T. Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats. Eur J Clin Invest 2003;33:1006–1012
10.
Zurück zum Zitat Kisseleva T, Brenner DA. Anti-fibrogenic strategies and the regression of fibrosis. Best Pract Res Clin Gastroenterol 2011;25:305–317 Kisseleva T, Brenner DA. Anti-fibrogenic strategies and the regression of fibrosis. Best Pract Res Clin Gastroenterol 2011;25:305–317
11.
Zurück zum Zitat Bataller R, Ginès P, Nicolás JM, Görbig MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V, Rodés J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000;118:1149–1156 Bataller R, Ginès P, Nicolás JM, Görbig MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V, Rodés J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000;118:1149–1156
12.
Zurück zum Zitat Yang L, Bataller R, Dulyx J, Coffman TM, Ginès P, Rippe RA, Brenner DA. Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol 2005;43:317–323 Yang L, Bataller R, Dulyx J, Coffman TM, Ginès P, Rippe RA, Brenner DA. Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol 2005;43:317–323
13.
Zurück zum Zitat Bataller R, Schwabe RF, Choi YH, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003;112:1383–1394 Bataller R, Schwabe RF, Choi YH, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003;112:1383–1394
14.
Zurück zum Zitat Wei Y, Clark SE, Morris EM, Thyfault JP, Uptergrove GME, Whaley-Connell AT, Ferrario CM, Sowers JR, Ibdah JA. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol 2008;49:417–428 Wei Y, Clark SE, Morris EM, Thyfault JP, Uptergrove GME, Whaley-Connell AT, Ferrario CM, Sowers JR, Ibdah JA. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol 2008;49:417–428
15.
Zurück zum Zitat Moreno M, Ramalho LN, Sancho-Bru P, et al. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol 2009;296:G147–G156 Moreno M, Ramalho LN, Sancho-Bru P, et al. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol 2009;296:G147–G156
16.
Zurück zum Zitat Munshi MK, Uddin MN, Glaser SS. The role of the renin-angiotensin system in liver fibrosis. Exp Biol Med (Maywood) 2011;236:557–566 Munshi MK, Uddin MN, Glaser SS. The role of the renin-angiotensin system in liver fibrosis. Exp Biol Med (Maywood) 2011;236:557–566
17.
Zurück zum Zitat Lubel JS, Herath CB, Burrell LM, Angus PW. Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. J Gastroenterol Hepatol 2008;23:1327–1338 Lubel JS, Herath CB, Burrell LM, Angus PW. Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. J Gastroenterol Hepatol 2008;23:1327–1338
18.
Zurück zum Zitat Kim G, Kim J, Lim YL, Kim MY, Baik SK. Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review. Hepatol Int 2016. doi: 10.1007/s12072-016-9705-x Kim G, Kim J, Lim YL, Kim MY, Baik SK. Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review. Hepatol Int 2016. doi: 10.1007/s12072-016-9705-x
19.
Zurück zum Zitat Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: concept to treatment. J Hepatol 2015;62:S15–S24 Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: concept to treatment. J Hepatol 2015;62:S15–S24
Metadaten
Titel
Targeting the renin–angiotensin system in liver fibrosis
verfasst von
Pau Sancho-Bru
Pere Ginès
Publikationsdatum
31.05.2016
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 5/2016
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-016-9740-7

Weitere Artikel der Ausgabe 5/2016

Hepatology International 5/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.